Carcinoembryonic antigen expression in stages I and II breast cancer: Its relationship with clinicopathologic factors

Human Pathology

Volumn 27, Issue 3, 1996, Pages 297-301

  Sundblad, Alberto S ^a,b   Pellicer, E Monica ^a   Ricci, Lila ^a  

^a UNIVERSIDAD NACIONAL DE MAR DEL PLATA   (Argentina)

^b HOSPITAL PRIVADO DE COMUNIDAD   (Argentina)

Author keywords

breast cancer; carcinoembryonic antigen; immunohistochemistry; prognosis

Indexed keywords

CARCINOEMBRYONIC ANTIBODY; CARCINOEMBRYONIC ANTIGEN; ESTROGEN RECEPTOR;

ADULT; AGED; ANTIGEN EXPRESSION; ARTICLE; BREAST CANCER; CANCER GRADING; CANCER RECURRENCE; CANCER STAGING; CANCER SURVIVAL; FEMALE; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; LYMPH NODE METASTASIS; MAJOR CLINICAL STUDY; PROGNOSIS; TUMOR VOLUME;

EID: 0030010117     PISSN: 00468177     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0046-8177(96)90072-6     Document Type: Article

References (37)

1. Rosen PP, Groshan S, Kinne DW, et al: Factors influencing prognosis in node-negative breast carcinoma: Analyses of 767 T1N0M0/T2N0M0 patients with long-term follow-up. J Clin Oncol 11:2090-2100, 1993
2. Henderson IC: Adjuvant chemotherapy for early breast cancer. Br J Cancer 61:652-654, 1990
3. Shousha S, Godfrey VM, Scheuer PJ: Carcinoembryonic antigen in breast cancer tissue: A useful prognostic indicator. Br J Med 24:777-779, 1979
4. Mansour EG, Haster M, Park CH, et al: Tissue and plasma carcinoembryonic antigen in early breast cancer: A prognostic factor. Cancer 51:1243-1248, 1983
5. Walker RA: Demonstration of carcinoembryonic antigen in human breast carcinomas by the immunoperoxidase technique. J Clin Pathol 33:356-360, 1980
6. Colomer R, Ruibal A, Salvador L: Circulating tumor marker level in advanced breast carcinoma correlates with the extent of metastatic disease. Cancer 64:1674-1681, 1989
7. Waalkes TP, Enterline JP, Shaper JH, et al: Biological markers for breast carcinoma. Cancer 53:644-651, 1984 (suppl)
8. Kuhajda FP, Offutt LE, Mendelsohn G: The distribution of carcinoembryonic antigen in breast carcinoma: Diagnostic and prognostic implications. Cancer 52:1257-1264, 1983
9. Shousha S, Lyossitis T: Correlation of carcinoembryonic antigen in tissue sections with spread of mammary carcinoma. Histopathology 2:433-447, 1978
10. Eskelinen M, Lipponen P, Syrjanen K: Expression of tumour markers CA50, CEA and TPA in female breast carcinoma as related to histopathological findings and survival. Anticancer Res 12:91-95, 1992
11. Esteban JM, Felder B, Ahn C, et al: Prognostic relevance of carcinoembryonic antigen and estrogen receptor status in breast cancer patients. Cancer 74:1575-1583, 1994
12. Wagener C, Clark BR, Rickard KJ, et al: Monoclonal antibodies for carcinoembryonic antigen and related antigens as a model system: Determination of affinities and specificities of monoclonal antibodies by using biotin-labeled antibodies and avidin as precipitating agent in a solution phase immunoassay. J Immunol 130:2302-2307, 1983
13. Nap M, Ten Hoor KA, Fleuren GJ: Cross reactivity with normal antigens in commercial anti-CEA sera, used for immunohistology: The need for tissue controls and absortions. Am J Clin Pathol 79:25-31, 1983
14. Price MR: Epitopes of carcinoembryonic antigen (CEA) defined by monoclonal antibodies. Br J Cancer 57:165-169, 1988
15. Neumaier M, Shively L, Chen FS, et al: Cloning for the genes for T84.66, an antibody that has a high specificity and affinity for carcinoembryonic antigen, and expression of chimeric human-mouse T84.66 genes in myeloma and Chinese hamster ovary cells. Cancer Res 50:2128-2134, 1990
16. Esteban JM, Paxton R, Mehta P, et al: Sensitivity and specificity of Gold types 1 to 5 anticarcinoembryonic antigen monoclonal antibodies: Immunohistologic characterization in colorectal cancer and normal tissues. HUM PATHOL 24:322-328, 1993
17. Sundblad AS, Pellicer EM, Mehta P, et al: Expresión de p53 en el carcinoma gástrico. Su valor pronostico. Medicina 54:216-220, 1994
18. BMDP Statistical Software Package: Version 7.0. University of California Press, 1994
19. Goldenberg DM, Sharkey RM, Primus FJP: Immunohistochemical detection of carcinoembryonic antigen in conventional histopathology specimens. Cancer 42:1546-1553, 1978
20. Robertson JF, Ellis IO, Bell J, et al: Carcinoembryonic antigen immunocytochemistry in primary breast cancer. Cancer 64:1638-1645, 1989
21. Hammarstrom S, Shively JE, Paxton RJ, et al: Antigenic sites in carcinoembryonic antigen. Cancer Res 49:4852-4858, 1989
22. Robbins PF, Eggensperger D, Qi C, et al: Definition of the expression of the human carcinoembryonic antigen and non-specific cross-reacting antigen in human breast and lung carcinomas. Int J Cancer 53:892-897, 1993
23. Schwartz MR, Randolph RL, Panko WB: Carcinoembryonic antigen and steroid receptor in the cytosol of carcinoma of the breast: Relationship to pathologic and clinical features. Cancer 55:2464-2471, 1985
24. Bocker W, Schweikhart G, Pollow K, et al: Immunohistochemical demonstration of carcinoembryonic antigen (CEA) in 120 mammary carcinomas and its correlation with tumor type, grading, staging plasma-cea, and biochemical receptor status. Pathol Res Pract 180:490-497, 1985
25. Glon M, Mione R, Dittadi R, et al: Carcinoembryonic antigen, ferritin, and tissue polypeptide antigen in serum and tissue: Relationship with the receptor content in breast carcinoma. Cancer 57:917-922, 1986
26. Hartfield R, Lopes JD, Lopes MTP, et al: Tissue carcinoembryonic antigen and estrogen receptor in human breast cancer. Int J Cancer 35:165-167, 1985
27. Gilchrist KW, Kalish L, Gould VE, et al: Immunostaining for carcinoembryonic antigen does not discriminate for early recurrence in breast cancer: The ECOG experience. Cancer 56:351-355, 1985
28. Schwarte M: Carcinoembryonic antigen and estrogen receptor: A prognostic duo in breast cancer. Cancer 74:1519-1522, 1994 (editorial)
29. Fisher ER, Redmond C, Fisher B: Pathologic findings from the National Surgical Adjuvant Breast and Bowel Project (protocol no. 4). VI. Discriminants for five-year treatment failure. Cancer 46:908-918, 1980
30. Carter CL, Allen C, Henson DE: Relation of tumor size, lymph node status and survival in 24,740 breast cancer cases. Cancer 63:181-187, 1989
31. Neville AM, Bettelheim R, Gelber RD, et al: Factors predicting treatment responsiveness and prognosis in node-negative breast cancer. J Clin Oncol 10:696-705, 1992
32. Seshadri R, Firgaira FA, Horsfall DJ, et al: Clinical significance of HER2/neu oncogene amplification in primary breast cancer. J Clin Oncol 11:1936-1942, 1993
33. Silvestrini R, Veneroni S, Daidone MG, et al: The bcl-2 protein: A prognostic indicator strongly related to p53 in lymph nodenegative breast cancer patients. J Natl Cancer Ins 86:499-504, 1994
34. Fielding LP, Fenoglio-Preiser C, Freedman LS: The future of prognostic factors in outcome prediction for patients with cancer. Cancer 70:2367-2377, 1992
35. Battifora H: Assessment of antigen damage in immunohistochemistry: The vimentin internal control. Am J Clin Pathol 96:669-671, 1991
36. Mansour EG, Ravdin PM, Dressier L: Prognostic factors in early breast carcinoma. Cancer 74:381-400, 1994
37. McGuire WL, Clark GM: Prognostic factors and treatment decisions in axillary-node-negative breast cancer. N Engl J Med 326:1756-1761, 1992